1. Short title This Act may be cited as the Affordable Pricing for Taxpayer-Funded Prescription Drugs Act of 2023 . 2. Reasonable price agreement (a) In general All Federal agencies providing or receiving research funding, through a grant, contract, cooperative agreement, or other agreement, shall require in such agreement, and in any license of the rights to a patent or regulatory test data for a biomedical product or service, that the price of any biomedical product or service developed with the benefit of such research be reasonable (as determined by the Secretary) unless the Secretary waives such reasonable price obligation under subsection (d). (b) Prohibition against charging prices higher than in other large economies with high incomes (1) In general For purposes of subsection (a), any reasonable pricing formula shall ensure, without prejudice to any other standards or negotiated provisions for reasonable pricing, that residents of the United States are not charged more for the biomedical product or service involved than the reference price for countries with large economies and high incomes. (2) Reference price For purposes of paragraph (1), the phrase reference price for countries with large economies and high incomes means— (A) the median price charged for the biomedical product or service involved in Canada and the additional six reference countries